Liposomal amphotericin is indicated in adults and children aged 1 month to 18 years old for:
• the treatment of severe systemic and/or deep mycoses;
• the treatment of visceral leishmaniasis in immunocompetent patients including both adults and children;
• the empirical treatment of presumed fungal infections in febrile neutropenic patients, where the fever has failed to respond to broad spectrum antibiotics and appropriate investigations have failed to define a bacterial or viral cause.
Infections successfully treated with liposomal amphotericin include: disseminated candidiasis, aspergillosis, mucormycosis, chronic mycetoma, cryptococcal meningitis and visceral leishmaniasis.
Liposomal amphotericin should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests.
Bortezomib 2.5 mg/ml Solution for Injection as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.
Bortezomib 2.5 mg/ml Solution for Injection in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Bortezomib 2.5 mg/ml Solution for Injection in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Bortezomib 2.5 mg/ml Solution for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation
Omeprazole capsules are indicated for:
Adults
• Treatment of duodenal ulcers
• Prevention of relapse of duodenal ulcers
• Treatment of gastric ulcers
• Prevention of relapse of gastric ulcers
• In combination with appropriate antibiotics, Helicobacter pylori (H. pylori) eradication in
peptic ulcer disease
• Treatment of NSAID-associated gastric and duodenal ulcers
• Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk
• Treatment of reflux oesophagitis
• Long-term management of patients with healed reflux oesophagitis
• Treatment of symptomatic gastro-oesophageal reflux disease
• Treatment of Zollinger-Ellison syndrome
Paediatric use
Children over 1 year of age and ≥ 10 kg
• Treatment of reflux oesophagitis
• Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease
Children and adolescents over 4 years of age
• In combination with antibiotics in treatment of duodenal ulcer caused by H. pylori
PROGESTERONE indicated in adult women.
Oral Route:
Gynaecological:
- Disorders due to progesterone insufficiency, Particularly:
- premenstrual syndrome,
- menstrual irregularities with dysovulation or anovulation,
- benign breast disorders,
- peri-menopause.
- treatment of menopause (in addition to oestrogen therapy).
- sterility due to luteal failure.
Obstetric:
- Threatened miscarriage or prevention of repeated miscarriage due to proven luteal insufficiency.
- Threatened premature delivery.
Vaginal Route:
- Subfertility or primary/secondary infertility due to partial or total luteal phase deficiency (in particular: irregular ovulation, supplementation of the luteal phase during in vitro fertilisation, egg donations).
- Threat of miscarriage or prevention of recurrent miscarriages due to luteal phase deficiency.
- Prevention of a premature singleton birth in women at risk, with a short cervical length of [less or equal] 25 mm measured between weeks 16 and 24 of pregnancy (weeks 18 and 26 of amenorrhoea)
Treatment of prostate cancer in the following settings:
• In the treatment of metastatic prostate cancer where Goserelin acetate has demonstrated comparable survival benefits to surgical castrations
• In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Goserelin acetate has demonstrated comparable survival benefits to an anti-androgen
• As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Goserelin acetate has demonstrated improved disease-free survival and overall survival
• As neo-adjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer where Goserelin acetate has demonstrated improved disease-free survival
• As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where
Goserelin acetate has demonstrated improved disease-free survival
Goserelin acetate 10.8 mg is indicated in the management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre and peri menopausal women.
This medicinal product is for diagnostic use.
Diagnostic indications
Cardiac, circulatory and micro-circulatory diagnostics:
·measurement of cardiac output and stroke volume
·measurement of circulating blood volumes
·measurement of cerebral perfusion
Liver function diagnostics:
·measurement of liver blood flow
·measurement of excretory function of the liver
Ophthalmic angiography diagnostics:
·measurement of perfusion of the choroid
• indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
• Treatment of diabetes insipidus (excluding nephrogenic diabetes insipidus).
• Control of bleeding esophageal varices.
Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); Age ≥ 75 years; hot failure (NYHA Class ≥ II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults
Donepezil Hydrochloride is indicated for the symptomatic treatment of mild to moderately severe Alzheimer"s dementia.
Registration
NCE
OLIMEL N12E
Glucose With Calcium Solution, Amino Acid With Electrolytes Solution And Lipid Emulsion,Glucose With Calcium Solution,Amino Acid With Electrolytes Solution,Lipid Emulsion
Glucose With Calcium Solution, Amino Acid With Electrolytes Solution And Lipid Emulsion,Glucose With Calcium Solution,Amino Acid With Electrolytes Solution,Lipid Emulsion
الاستخدامات الطبية المعتمدة
OLIMEL N12E is indicated for parenteral nutrition for adults and children greater than 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
